Extended Data Table 2 Exploratory subgroup analysis of progression-free survival according to homologous-recombination status

From: Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial

  1. BRCAmut, carrying mutation in the breast cancer susceptibility genes BRCA1 or BRCA2; BRCAwt, BRCA wild-type; CI, confidence interval; HR, hazard ratio; HRD, homologous-recombination repair deficiency; HRP, homologous-recombination proficiency; NR, not reached; PFS, progression-free survival.
  2. The PFS results in patients with undetermined HRD status were similar to those in patients with available HRD testing data as well as in the intention-to-treat population.
Back to article page